RemeGen Collaborates with Innovent Bio
Monday, July 10, 2023
RemeGen has announced a clinical trial and supply agreement with Innovent Biologics.
The collaboration between RemeGen and Innovent Biologics focuses on conducting clinical trials to explore combination therapies using the novel antibody-drug conjugates (ADCs), RC88 and RC108, along with the PD-1 inhibitor sintilimab injection (TYVYT®).
According to the agreement, Innovent will be responsible for supplying the clinical drug supplies of sintilimab, while RemeGen will conduct Phase I/IIa clinical studies in China. The purpose of these clinical trials is to evaluate the safety, tolerability, and preliminary efficacy of combining RC88 or RC108 with sintilimab in Chinese cancer patients.
The alliance with Innovent indeed represents a significant advancement in the research and commercialisation strategy of combination therapies involving RC88 and RC108. By combining RC88 and RC108 with sintilimab, the treatment approach becomes multifaceted, targeting multiple pathways involved in disease progression. These mechanisms are complementary and can help overcome or delay treatment resistance and provide an effective solution to unmet clinical needs.
Preliminary findings indicate that RC88 monotherapy has demonstrated antitumor activity against MSLN-expressing solid tumors and has a manageable safety profile. Combining RC88 with immune checkpoint inhibitors like PD-1/PD-L1 can induce immunogenic cell death (ICD), which activates T cells and enhances the tumour immune response by releasing signalling molecules.
